Reporting owner · CIK 0001763581

Schoenberg Mark

Visual SEC Form 4 history across 1 companies, 24 transactions and 5 filings.

CMOChief Medical OfficerUroGen Pharma Ltd.
Open-market mix
Latest filingSep 09, 2026, 06:37 PM
Filings5Form 4 records
Buying$00 purchases
Selling$3.1M8 sales
Net value−$3.1MBuys minus sells
Companies13 securities
Most recentSep 08, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-53Jan 25Jan 263Feb 261Aug 261Sep 26

Net value flow

Buys minus sells

Jan 25
−$50.7K
Jan 26
$0
Feb 26
−$145.2K
Aug 26
−$2.9M
Sep 26
−$37.4K

Transaction texture

Ownership and ticket size

Average P/S size$386K
Median P/S size$36.3K
Direct24
Indirect0
Sep 08, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern2Derivative Transactionfiling-context8Direct Ownershipfiling-context21Large Holdings Increaseholdings2Large Holdings Reductionholdings5Large Salesize2Repeat Sellerpattern1

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at UroGen Pharma Ltd. on Sep 08, 2026 valued at $37,383.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at UroGen Pharma Ltd. on Sep 08, 2026 valued at $37,383.

Review SEC filing

Associated companies

Visual map of known reporting history

URGNUroGen Pharma Ltd.24 transactions · latest Sep 09, 2026, 06:37 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
URGNSchoenberg Mark
CMO
exercise3.33k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
+16.8%02/0301/31
URGNSchoenberg Mark
CMO
exercise3.33k—M
Direct Ownership
+16.8%02/0301/31
URGNSchoenberg Mark
CMO
exercise6.66k—M
Direct Ownership
+16.8%02/0301/31
URGNSchoenberg Mark
CMO
exercise3.33k—M
Direct Ownership
+16.8%02/0301/31
URGNSchoenberg Mark
CMO
grant20.0k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—02/04/202501/31/2025
URGNSchoenberg Mark
CMO
exercise3.33k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
—02/04/202501/31/2025
URGNSchoenberg Mark
CMO
exercise3.33k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
—02/04/202501/31/2025
URGNSchoenberg Mark
CMO
exercise1.33k$0M
Derivative Transaction Direct Ownership
—02/04/202501/31/2025
URGNSchoenberg Mark
CMO
sale1.89k-$2.11MS
Cluster Selling Direct Ownership
—02/04/202501/31/2025
URGNSchoenberg Mark
CMO
exercise3.33k—M
Direct Ownership
—02/04/202501/31/2025

Schoenberg Mark Insider Activity FAQ

SEC Form 4 context

Who is Schoenberg Mark?

Schoenberg Mark is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001763581.

Which companies has Schoenberg Mark reported transactions for?

UroGen Pharma Ltd.

When was Schoenberg Mark's latest insider buy?

No open-market insider purchase is available for this period.

When was Schoenberg Mark's latest insider sale?

sale at UroGen Pharma Ltd. on Sep 08, 2026 valued at $37,383.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.